Publications
Below you can find a list of our published research.
Below you can find a list of our published research.
509 results
Cited 11 times since 1990 (0.3 per year) source: EuropePMC
The American journal of medicine, Volume 89, Issue 2, 1 1 1990, Pages 247-248 Decreased phenytoin level after carboplatin treatment. Dofferhoff AS, Berendsen HH, vd Naalt J, Haaxma-Reiche H, Smit EF, Postmus PE
Cited 1 times since 1990 (0 per year) source: EuropePMC
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, Volume 8, Issue 7, 1 1 1990, Pages 1281 Etoposide and mesothelioma. Smit EF, Berendsen HH, Postmus PE
Cited 24 times since 1990 (0.7 per year) source: EuropePMC
Seminars in oncology, Volume 17, Issue 1 Suppl 2, 1 1 1990, Pages 49-53 Single-agent oral etoposide for elderly small cell lung cancer patients. Carney DN, Grogan L, Smit EF, Harford P, Berendsen HH, Postmus PE
Among new patients with small cell lung cancer (SCLC), 20% to 25% are over 70 years of age and account for 8,000 cases annually in the United States. For such patients, intensive, aggressive, cytotoxic, combination chemotherapy is not often used because of its association with unacceptable morbidity and mortality rates. However, treatment of these patients is often indicated, if not demanded. Etoposide is among the most active agents for the treatment of SCLC; both oral (PO) and intravenous prep... Abstract
Cited 44 times since 1989 (1.3 per year) source: EuropePMC
Thorax, Volume 44, Issue 8, 1 1 1989, Pages 631-633 A phase II study of oral etoposide in elderly patients with small cell lung cancer. Smit EF, Carney DN, Harford P, Sleijfer DT, Postmus PE
Thirty five previously untreated patients with small cell lung cancer older than 70 years were treated with oral etoposide (800 mg/m2 over five consecutive days) every four weeks. Twenty two patients had extensive disease and 13 limited disease. The overall response rate was 71%. The median survival for patients with limited diseases was 16 (range 6-32) months and for patients with extensive disease nine (range 4-17) months. There was mild haematological toxicity and alopecia but no major toxici... Abstract
Cited 26 times since 1989 (0.7 per year) source: EuropePMC
British journal of cancer, Volume 60, Issue 1, 1 1 1989, Pages 116-120 Acute and cumulative effects of carboplatin on renal function. Sleijfer DT, Smit EF, Meijer S, Mulder NH, Postmus PE
Carboplatin, a cisplatinum analogue, has no reported nephrotoxicity in phase I/II studies, assessed by creatinine clearance. We prospectively determined renal function in 10 untreated lung cancer patients with normal baseline renal function, treated with carboplatin 400 mg m-2 day 1 and vincristine 2 mg day 1 and 8 every 4 weeks (max. five cycles) by means of clearance studies with 125I-sodium thalamate and 131I-hippurate to determine GFR and ERPF respectively. Tubular damage was monitored by ex... Abstract
Cited 1 times since 1989 (0 per year) source: EuropePMC
Annals of internal medicine, Volume 110, Issue 12, 1 1 1989, Pages 1034 Carboplatin and renal function. Smit EF, Sleijfer DT, Meijer S, Mulder NH, Postmus PE
Cited 1 times since 1989 (0 per year) source: EuropePMC
British journal of cancer, Volume 59, Issue 3, 1 1 1989, Pages 471-472 Phase I study of 21 days continuous infusion with vindesine. de Vries EG, Smit EF, Vendrig DE, Holthuis JJ, Mulder NH
Chest, Volume 95, Issue 3, 1 1 1989, Pages 709-710 Oral etoposide for a 95-year-old patient with small cell lung cancer. Smit EF, Sleijfer DT, Postmus PE
Cited 9 times since 1989 (0.3 per year) source: EuropePMC
Cancer chemotherapy and pharmacology, Volume 25, Issue 3, 1 1 1989, Pages 202-204 A phase II study of carboplatin and vincristine in previously treated patients with small-cell lung cancer. Smit EF, Berendsen HH, de Vries EG, Mulder NH, Postmus PE
A total of 28 previously treated patients with small-cell lung cancer were treated at relapse with 400 mg/m2 carboplatin and 2 mg vincristine on days 1 and 8, every 4 weeks. Ten partial responses (PRs) (37%) but no complete responses (CRs) were seen. Median survival after the start of second-line treatment was 120 days (range, 39-503 days). Toxicity of this regimen was moderate, including WHO grade 3/4 myelosuppression in 26% of courses (n = 66). Eight PRs were seen in a subgroup of 22 patients... Abstract